Reuters logo
BRIEF-Juno Therapeutics reports qtrly net loss per share $0.51
March 1, 2017 / 9:31 PM / 9 months ago

BRIEF-Juno Therapeutics reports qtrly net loss per share $0.51

March 1 (Reuters) - Juno Therapeutics Inc:

* Juno Therapeutics reports fourth quarter and 2016 financial results

* Juno Therapeutics Inc - 2017 cash burn guidance of $270 million to $300 million

* Juno Therapeutics Inc sees 2017 capital expenditures estimated to be between $22 million and $27 million

* Juno Therapeutics Inc sees 2017 operating burn estimated to be between $245 million and $275 million

* Juno Therapeutics Inc qtrly net loss per share $0.51

* Juno Therapeutics Inc qtrly revenue $21.2 million versus $ 4.2 million

* Q4 earnings per share view $-0.61, revenue view $14.6 million -- Thomson Reuters I/B/E/S

* Juno Therapeutics Inc qtrly net loss per share non-gaap $0.65

* Says “discontinuing development of jcar015 in r/r adult all to focus on defined cell product in this setting” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below